Cargando…

A glucagon analogue decreases body weight in mice via signalling in the liver

Glucagon receptor agonists show promise as components of next generation metabolic syndrome pharmacotherapies. However, the biology of glucagon action is complex, controversial, and likely context dependent. As such, a better understanding of chronic glucagon receptor (GCGR) agonism is essential to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinds, Charlotte E., Owen, Bryn M., Hope, David C. D., Pickford, Philip, Jones, Ben, Tan, Tricia M., Minnion, James S., Bloom, Stephen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604983/ https://www.ncbi.nlm.nih.gov/pubmed/34799628 http://dx.doi.org/10.1038/s41598-021-01912-0

Ejemplares similares

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
por: Hope, David C.D., et al.
Publicado: (2022)

Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
por: Scott, R., et al.
Publicado: (2018)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2021)

Increased food intake with oxyntomodulin analogues
por: Price, Samantha L., et al.
Publicado: (2015)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
por: Pickford, Phil, et al.
Publicado: (2021)

RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
por: Cegla, Jaimini, et al.
Publicado: (2017)

Hepatocyte cholesterol content modulates glucagon receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2022)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors
por: Jones, Ben, et al.
Publicado: (2020)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2020)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2020)

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
por: Kosinski, Jennifer R., et al.
Publicado: (2012)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
por: Tan, Tricia M., et al.
Publicado: (2013)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases
por: Cuenco, Joyceline, et al.
Publicado: (2017)

The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction
por: Jones, Ben, et al.
Publicado: (2021)

What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
por: Klair, Nimra, et al.
Publicado: (2023)

SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2019)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates
por: Thompson, W. Clayton, et al.
Publicado: (2016)

Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor
por: Jones, Ben J., et al.
Publicado: (2017)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
por: Kjaer, Marie, et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Body satisfaction and body weight: gender differences and sociodemographic determinants
por: Austin, S Bryn, et al.
Publicado: (2009)

Problem or solution: The strange story of glucagon
por: Scott, R.V., et al.
Publicado: (2018)

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
por: Deane, Adam M, et al.
Publicado: (2010)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
por: Adams, Jessica M., et al.
Publicado: (2018)

No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
por: Hope, David C. D., et al.
Publicado: (2018)

Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
por: Pedersen, Christina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pvqopnausliim6iqj4u94jruj9